// App-Quantinova.ai

519 : Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Researchers

Presenter

  • Carsten Denkert

Principal Investigators

  • Miguel Martin

  • Michael Untch

  • Herve R. Bonnefoi

  • Agnieszka Katarzyna Witkiewicz

  • Seock-Ah Im

  • Angela DeMichele

  • Laura van 't Veer

  • Nicole Mc Carthy

  • Karen A. Gelmon

  • Nicholas C. Turner

  • Federico Rojo

  • Peter A. Fasching

  • Julia Teply-Szymanski

  • Yuan Liu

  • Masakazu Toi

  • Michael Gnant

  • Karsten Ernst Weber

  • Sibylle Loibl

Medical Centers

  • Institute of Pathology, Philipps-University Marburg and UKGM Marburg, Marburg, Germany

  • Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Mannheim, Germany

  • Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Universidad Complutense de Madrid, GEICAM Breast Cancer Group, Madrid, Spain

  • HELIOS Klinikum Berlin-Buch, Berlin, Germany

  • Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY, Cancer Research Institute, College of Medicine, Seoul National University Hospital, Seoul, South Korea

  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, University of California, San Francisco, San Francisco, CA

  • Breast Cancer Trials Australia and New Zealand and University of Queensland, Brisbane, Australia

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • The Institute of Cancer Research: Royal Cancer Hospital, United Kingdom

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University...

  • Pfizer Inc, San Diego, CA

  • Department of Gastroenterology, Graduate School of Medicine Kobe University, Kobe, Japan

  • Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria

  • German Breast Group (GBG), Neu-Isenbug, Germany

Locations

  • Germany

  • Spain

  • France

  • Australia

  • Canada

  • United Kingdom

  • Japan

  • Austria

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Palbociclib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01864746

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved